The newest weight and diabetes medicines have been climbing a ladder — adding one hormone receptor at a time. Semaglutide hits one receptor, tirzepatide hits two, and retatrutide hits three. Retatrutide vs tirzepatide is the "triple vs dual" step on that ladder.
In plain terms: same basic family, one extra lever.
Counting receptors
These drugs mimic gut hormones ("incretins") that curb appetite and steady blood sugar. Each newer molecule adds another receptor to press:
| Tirzepatide | Retatrutide | |
|---|---|---|
| GLP-1 receptor | Yes | Yes |
| GIP receptor | Yes | Yes |
| Glucagon receptor | No | Yes |
| Description | Dual agonist ("twincretin") | Triple agonist |
| Status | FDA-approved | Investigational (in trials) |
- Tirzepatide engages GIP and GLP-1 — the "twincretin" (what is tirzepatide).
- Retatrutide adds the glucagon receptor. That third target is interesting because glucagon-receptor activity can raise energy expenditure — potentially burning more, on top of eating less.
The crucial status difference
This is the honesty that matters most: tirzepatide is approved; retatrutide is not. Tirzepatide has completed large trials and is a marketed medicine. Retatrutide is still investigational, working through the trial process. So this isn't a comparison of two available drugs — it's an approved drug versus a very promising candidate.
What the trials actually found
| Trial | People | Key result | Year |
|---|---|---|---|
| SURMOUNT-1 (tirzepatide)2 | Adults with obesity, no diabetes | Up to ~20.9% average weight loss over 72 weeks on the top dose | 2022 |
| Retatrutide phase 2 (Jastreboff)1 | 338 adults with obesity | Up to ~24% average weight loss on the 12 mg dose over 48 weeks | 2023 |
Read those side by side carefully, because the trials weren't the same length (72 vs 48 weeks) and weren't head-to-head. The retatrutide figure is striking — but it comes from an earlier-stage, shorter, non-comparative trial. You can't cleanly conclude "retatrutide beats tirzepatide" from two separate studies.
Latest research (2023)
The headline is retatrutide's phase-2 obesity trial, published in the *New England Journal of Medicine* in 20231. In 338 adults with obesity, once-weekly retatrutide produced dose-dependent weight loss, reaching an average of about 24% at the highest dose (12 mg) by week 48 — with the placebo group down only ~2%. At the 24-week primary endpoint, the top doses were already around 17–18%.
Two honest caveats keep this in proportion:
- It's phase 2. These results still need confirmation in the larger, longer phase-3 trials now underway before retatrutide could be approved.
- It wasn't a head-to-head. No trial has yet directly pitted retatrutide against tirzepatide, so the apparent edge is a cross-study impression, not a proven win.
We update this section as the phase-3 program reports.
The through-line
All of these build on the GLP-1 foundation (GLP-1 receptor agonists explained); each rung adds a receptor. Retatrutide vs tirzepatide is fundamentally triple vs dual — one added lever on the same incretin system, with one now approved and the other still proving itself. Educational overview only, not medical advice.